Long-term data from the ZUMA-5 trial demonstrate durable responses with axicabtagene ciloleucel, offering new hope for patients with relapsed or refractory follicular lymphoma.
The Challenge of Relapsed Indolent Lymphoma
For patients with follicular lymphoma who relapse after multiple lines of therapy, treatment options have historically offered diminishing returns. While indolent
